Journal of Thrombosis and Thrombolysis

, Volume 27, Issue 2, pp 220-222

First online:

A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab

  • Semir PasaAffiliated withDepartment of Hematology, Medical Faculty, Dicle University Email author 
  • , Abdullah AltintasAffiliated withDepartment of Hematology, Medical Faculty, Dicle University
  • , Timucin CilAffiliated withDepartment of Oncology, Medicine Faculty, Dicle University
  • , Ramazan DanisAffiliated withDepartment of Nephrology, Medicine Faculty, Dicle University
  • , Orhan AyyildizAffiliated withDepartment of Hematology, Medical Faculty, Dicle University
  • , Ekrem MuftuogluAffiliated withDepartment of Hematology, Medical Faculty, Dicle University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Current treatment options of essential mixed cryoglobulinemia (EMC); include immunosuppressive approaches, such as corticosteroids, cyclophosphamide, plasma exchange, other cytotoxic drugs in moderate to severe manifestations. Some controlled studies have been carried out to assess the efficacy of anti-CD20 monoclonal antibody, rituximab in patients with hepatitis C (HCV) related cryoglobulinemia (CG) and in patients with autoimmune disorders. Recent trials and some case reports demonstrate a beneficial role for rituximab in HCV related mixed CG. Although, the published evidence for treatment of EMC with rituximab is restricted to case reports, which have shown positive results. Several diseases include lymphoproliferative and myeloproliferative disorders, solid tumors, immunological disorders, cardiovascular disorders and some drugs associated with acquired von Willebrand disease (avWD). CG, which is a kind of immune complex disease, may be related with development of autoantibodies to various autoantigens. In this present case report, we showed the efficacy of rituximab in a 21-year-old female patient, suffered from neuropathy and arthralgia related with EMC, and developed avWD, presented with mucosal bleeding associated with CG. von Willebrand factor activity of our patient also increased with controlling the underlying disease, EMC by rituximab. This case demonstrate that rituximab may be an effective treatment option in EMC and avWD mainly related to CG.


Essential mixed cryoglobulinemia Acquired von Willebrand disease Rituximab